利福昔明治疗急性感染性腹泻45例临床观察

Clinical study of rifaximin in 45 patients with acute infectious diarrhea

目的评价利福昔明治疗急性感染性腹泻的临床疗效及安全性。方法采用随机双盲双模拟平行对照试验。治疗组45例,每次给予利福昔明0.2g,口服4次/d,同时给予左氧氟沙星模拟安慰片2片(0.2g),口服2次/d,疗程3d;对照组43例,每次给予左氧氟沙星0.2g,口服2次/d,同时给予利福昔明模拟安慰片2片(0.2g),口服4次/d,疗程3d。结果治疗组与对照组临床痊愈率分别为77.8%和79.1%,两组间临床痊愈率及综合疗效比较差异均无显著性(P>0.05)。且主要症状消失率、累计止泻率和止泻时间、大便常规、性状及次数复常率比较差异亦无显著性(P>0.05)。治疗前两组大便细菌培养阳性率分别为35.6%和30.2%。治疗后细菌清除率分别为93.8%和100.0%,不良反应发生率分别为2.2%和4.7%,经统计学处理,差异均无显著性(P>0.05)。结论利福昔明治疗急性感染性腹泻安全、有效。

[Objective] To evaluate the efficacy and safety of rifaximin in the treatment of acute infectious diarrhea. [Methods] 88 patients were recruited into the randomized, double blind, and parallel-control trial. 45 patients in the treatment group were given 0.2 g of rifaximin, po, qid and 2 levofloxacin dummy tablets （0.2 g）, po, bid. 43 patients in the control group were given each 0.2 g of levofloxacin, po, bid and 2 rifaximin dummy tablets （0.2 g）, po, qid. The course of treatment in both groups lasted 3 days. [Results] The recovery rates were 77.8% and 79.1% in the treatment and control group respectively. There were no remarkable differences between the two groups in recovery rates and the comprehensive efficacy. The rate and time of diarrhea disappeared. The normalization rate of stool routine, stool character and defecation frequency, and the relieve rate of main symptoms were similar in the two groups. The bacterium positive rates were 35.6% and 30.2% before treatment. The bacterial clearance rates were 93.8% and 100.0%, and the rates of side effect were 2.2 % and 4.7% in two groups respectively. No remarkable dif- ferences in the rates of side effect were observed in two groups. [Conclusion] Rifaximin is safe and effective in the treatment for acute infectious diarrhea.